Medios AG Cuts EBITDA, Shares Down 8.5%

Medios AG Guidance Update

Medios AG (ticker ETR:ILM), a Germany‑based specialty pharmaceutical company, saw its shares decline 8.5% after announcing a reduction in its full‑year 2026 adjusted EBITDA guidance. The new guidance range is €88 million to €92 million, narrowed from the prior €94 million‑€102 million outlook. At the same time, the company increased its 2026 revenue guidance to a range of €2.1 billion‑€2.16 billion, up from €2.0 billion‑€2.12 billion previously indicated.

Preliminary figures for the first half of 2026 show revenue exceeding €1 billion, representing growth versus the prior year, while adjusted EBITDA for the same period declined modestly year‑on‑year.

Management attributed the downward revision of EBITDA to continued price pressure in the Pharmaceutical Supply segment, restricted reimbursement eligibility affecting the medical‑cannabis business, and slightly weaker performance in the International Business segment.

The revenue uplift is driven by expectations of higher sales despite the challenges noted above. No further commentary on future actions or mitigation measures was provided.